Dermatology

Laura Ferris, MD, PhD, reflects on her unexpected path to department chair as well as the lessons of her journey as a leader in academic medicine.

This analysis of patients with atopic dermatitis in the BIOREP registry spotlight the safety and efficacy of lebrikizumab therapy.

This analysis suggests that GLP-1 RAs provide promise for those with HS and obesity and potentially for such individuals without obesity via immunological impacts.

The G-EPOSS study demonstrated the long-term impacts of guselkumab on patients’ psoriasis symptoms, sexual impairment, and perceived stigmatization.

Findings highlight an association between psoriasis and risks of all-cause, cardiovascular, infection-related, and suicide mortality.

Meta-analysis finds omalizumab and remibrutinib most effective for chronic urticaria unresponsive to antihistamines; cyclosporine has greater risks.

Recent interview- and survey-based research has quantified the extent to which GPP impacts patients, examining both symptoms and mental health outcomes.

Real-world review finds Black patients report fewer dupilumab-related adverse events than White patients.

Providing nurses and MAs with an educational video on standardized hair loss photo techniques increased the quantity and quality of documented pictures.

In a Chinese cohort, baricitinib achieved high hair regrowth rates in alopecia areata, totalis, universalis, and eyebrow/eyelash loss, with no serious adverse events.

This August 2025 News Update spotlights Ugonabo’s career journey, her award and its story, and the growing importance of tailored dermatologic care for diverse skin tones.

This systematic review and meta-analysis found that biologic switching was shown to be safe and effective among patients with psoriasis.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the DERM2025 meeting.

This summary of dermatology news coverage from the month of August 2025 highlights some of the most notable stories in this medical subfield.

These data from the ICONIC-LEAD study were presented at DERM 2025, highlighting the efficacy and safety of icotrokinra in patients with psoriasis.

In this summary of coverage at the DERM 2025 conference, a list of notable stories highlighting acne management strategies is highlighted.

In this list of the top 5 posters featured at the DERM 2025 conference, a variety of recent data are spotlighted in alopecia areata, atopic dermatitis, and other disease states.

News coverage from DERM 2025 in the field of psoriasis is highlighted in this post-conference summary.

This summary covers a variety of notable DERM 2025 conference news highlights, specifically in the area of alopecia areata.

This list highlights a variety of notable DERM 2025 conference news coverage, specifically in the field of atopic dermatitis.

The PAISLEY CLE trial findings highlight deucravacitinib’s efficacy among patients with cutaneous lupus, including those with concurrent SLE.

This clinical episode of Skin of Color Savvy highlights the work of the International Alliance for Global Health Dermatology (GLODERM) and a new collaboration between GLODERM and SOCS.

This segment of Hebert’s DERM 2025 interview highlights additional conclusions from her team’s data on roflumilast in atopic dermatitis among infants and toddlers.

In a DERM 2025 conference interview, Hebert highlights takeaways from her team’s findings on roflumilast cream in patients aged 3 months to 2 years with atopic dermatitis.

This FDA News Month in Review provides a round-up of regulatory decisions from July 2025.